Yongchuan Gu

发表

Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma

W. Wilson, S. Jamieson, M. Abbattista, 2015, Cancer biology & therapy.

The dual PI3K/mTOR inhibitor NVP-BEZ235 prevents epithelial-mesenchymal transition induced by hypoxia and TGF-β1.

Qiaojun He, Bo Yang, Si-da Liao, 2014, European journal of pharmacology.

ROLES OF BIOTRANSFORMATION IN THE ANTITUMOUR ACTIVITY AND TOXICOLOGY OF THE HYPOXIA-ACTIVATED PRE- PRODRUG PR-104

Yongchuan Gu, 2010 .

Drug‐DNA adducts as biomarkers for metabolic activation of the nitro‐aromatic nitrogen mustard prodrug PR‐104A

W. Wilson, K. Deng, S. Sturla, 2018, Biochemical pharmacology.

Novel potent HIF-1 inhibitors for the prevention of tumor metastasis: discovery and optimization of 3-aryl-5-indazole-1,2,4-oxadiazole derivatives

Qiaojun He, Bo Yang, Ji Cao, 2015 .

Reductive Metabolism Influences the Toxicity and Pharmacokinetics of the Hypoxia-Targeted Benzotriazine Di-Oxide Anticancer Agent SN30000 in Mice

W. Wilson, Courtney Lynch, K. Hicks, 2017, Front. Pharmacol..

Stability of vincristine sulfate, doxorubicin hydrochloride and etoposide phosphate admixtures in polyisoprene elastomeric pump supporting transition of the EPOCH regimen to outpatient care

D. Svirskis, Yongchuan Gu, L. Berkahn, 2019, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Photodegradation of the benzotriazine 1,4-Di-N-oxide hypoxia-activated prodrug SN30000 in aqueous solution.

W. Wilson, K. Hicks, M. Hay, 2014, Journal of pharmaceutical sciences.

Novel nitroimidazole alkylsulfonamides as hypoxic cell radiosensitisers.

W. Wilson, R. Anderson, M. Bonnet, 2014, Bioorganic & medicinal chemistry.

LC–MS–MS Study of the Pharmacokinetics of a 9-β-Dihydro-9,10-O-acetal Derivative of Docetaxel in Rats and Beagle Dogs

Guangji Wang, F. Pruijn, Yongchuan Gu, 2008 .

Selective treatment of hypoxic tumor cells in vivo: phosphate pre-prodrugs of nitro analogues of the duocarmycins.

W. Denny, W. Wilson, G. Atwell, 2011, Angewandte Chemie.

Next-Generation Hypoxic Cell Radiosensitizers: Nitroimidazole Alkylsulfonamides.

W. Wilson, R. Anderson, M. Bonnet, 2018, Journal of medicinal chemistry.

Zinc Finger Nuclease Knock-out of NADPH:Cytochrome P450 Oxidoreductase (POR) in Human Tumor Cell Lines Demonstrates That Hypoxia-activated Prodrugs Differ in POR Dependence*

W. Wilson, J. Smaill, F. Pruijn, 2013, The Journal of Biological Chemistry.

Effect of POR knockout on hypoxic prodrug activation

W. Wilson, J. Smaill, F. Pruijn, 2013 .

Improved HPLC method for the simultaneous determination of tramadol and O-desmethyltramadol in human plasma.

J. P. Fawcett, Yongchuan Gu, 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Hypoxia-Induced WSB1 Promotes the Metastatic Potential of Osteosarcoma Cells.

Ning Zhang, Bo Yang, Rong Dong, 2015, Cancer research.

A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells.

S. Bohlander, M. Konopleva, W. Wilson, 2014, Biochemical pharmacology.

The flavoprotein FOXRED2 reductively activates nitro-chloromethylbenzindolines and other hypoxia-targeting prodrugs.

C. Print, W. Wilson, D. Hurley, 2014, Biochemical pharmacology.

Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cells.

Y. Pommier, W. Wilson, S. Powell, 2008, Cancer research.

Mechanism of Action and Preclinical Antitumor Activity of the Novel Hypoxia-Activated DNA Cross-Linking Agent PR-104

Rachelle S. Singleton, W. Denny, W. Wilson, 2007, Clinical Cancer Research.

Hypoxia-selective radiosensitisation by SN38023, a bioreductive prodrug of DNA-dependent protein kinase inhibitor IC87361.

W. Wilson, W. Wong, F. Hunter, 2019, Biochemical pharmacology.

Transport and bioavailability studies of astragaloside IV, an active ingredient in Radix Astragali.

Guangji Wang, J. A, Guoyu Pan, 2004, Basic & clinical pharmacology & toxicology.

Determination of Astragaloside IV in rat plasma by liquid chromatography electrospray ionization mass spectrometry.

Guangji Wang, J. P. Fawcett, Yongchuan Gu, 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia

Hoang Q. Nguyen, P. Thall, E. Estey, 2015, Haematologica.

Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A

W. Wilson, L. Thompson, G. Atwell, 2009, Molecular Cancer Therapeutics.

Initial testing of the hypoxia‐activated prodrug PR‐104 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2011, Pediatric blood & cancer.

Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs.

J. Moffat, T. Ketela, K. Brown, 2015, Cancer research.

Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice

W. Wilson, Xueying Sun, K. Patel, 2011, Cancer Chemotherapy and Pharmacology.

Correction: Hypoxia-Induced WSB1 Promotes the Metastatic Potential of Osteosarcoma Cells

Qiaojun He, Bo Yang, Ji Cao, 2020, Cancer Research.

Rapid and sensitive ultra-high-pressure liquid chromatography-tandem mass spectrometry analysis of the novel anticancer agent PR-104 and its major metabolites in human plasma: Application to a pharmacokinetic study.

W. Wilson, Yongchuan Gu, 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

The SIRT2-mediated deacetylation of AKR1C1 is required for suppressing its pro-metastasis function in Non-Small Cell Lung Cancer

Qiaojun He, Bo Yang, Ji Cao, 2020, Theranostics.

Metabolism and Excretion of the Novel Bioreductive Prodrug PR-104 in Mice, Rats, Dogs, and Humans

W. Wilson, G. Atwell, Yongchuan Gu, 2010, Drug Metabolism and Disposition.

A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients

W. Wilson, M. McKeage, A. Hill, 2011, BMC Cancer.

Glucuronidation of Anticancer Prodrug PR-104A: Species Differences, Identification of Human UDP-Glucuronosyltransferases, and Implications for Therapy

W. Wilson, Yongchuan Gu, M. Tingle, 2011, Journal of Pharmacology and Experimental Therapeutics.

Hypoxic selectivity and solubility--investigating the properties of A-ring substituted nitro seco-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-ones (nitroCBIs) as hypoxia-activated prodrugs for antitumor therapy.

W. Denny, W. Wilson, R. Anderson, 2010, Bioorganic & medicinal chemistry.

Analysis of the hypoxia-activated dinitrobenzamide mustard phosphate pre-prodrug PR-104 and its alcohol metabolite PR-104A in plasma and tissues by liquid chromatography-mass spectrometry.

W. Wilson, K. Patel, K. Hicks, 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

DMD # 30973-1-Metabolism and Excretion of the Novel Bioreductive Prodrug PR-104 in Mice , Rats , Dogs and Humans

W. Wilson, G. Atwell, Yongchuan Gu, 2009 .

PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours

W. Wilson, J. Rajendran, M. McKeage, 2012, BMC Cancer.

The flavoprotein FOXRED2 reductively activates nitro-chloromethylbenzindolines and other hypoxia-targeting prodrugs.

S. Richter, F. Hunter, J. Jaiswal, 2014, Biochemical pharmacology.

Photodegradation of the benzotriazine 1,4-Di-N-oxide hypoxia-activated prodrug SN30000 in aqueous solution.

W. Wilson, K. Hicks, M. Hay, 2014, Journal of pharmaceutical sciences.

Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cells.

Y. Pommier, W. Wilson, S. Powell, 2008, Cancer Research.